Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Cutis marmorata telangiectatica congenita (CMTC) is a rare, deep purple, marble- or net-like birthmark. It is mostly cosmetic, and while it is present at birth, it fades considerably over a child's first year.
The Vascular Anomalies Center at Boston Children's takes an interdisciplinary approach to care with every child they see. While cutis marmorata telangiectatica congenita is typically only a cosmetic issue, on your first visit to clinic, several VAC specialists will often review you child's case at the same time. Our experience in treating numerous patients with CMTC gives us the depth of knowledge about what symptoms to look for and how to plan treatment accordingly.
Once a diagnosis and the extent of the disease is confirmed, the team works with you to develop and carry out a comprehensive and coordinated care plan that matches your child's specific needs. The team brings the expertise of other Boston Children's departments and services as necessary to provide your child with the best care.
Cutis marmorata telangiectatica congenita: Reviewed by Marilyn Liang, MD,
© Boston Children's Hospital, 2015
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”